Cargando…
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), an...
Ejemplares similares
-
COVAD survey 2 long-term outcomes: unmet need and protocol
por: Fazal, Zoha Zahid, et al.
Publicado: (2022) -
Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey
por: Naveen, R., et al.
Publicado: (2023) -
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
por: Gil‐Vila, Albert, et al.
Publicado: (2022) -
High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey
por: Grignaschi, Silvia, et al.
Publicado: (2023) -
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol
por: Sen, Parikshit, et al.
Publicado: (2021)